Article

Simultaneous, cell-intrinsic downregulation of PD-1 and TIGIT enhances the effector function of CD19-targeting CAR T cells and promotes an early-memory phenotype

2020-11-08

Abstract excerpt

CD19-targeting chimeric antigen receptor (CAR) T cells have become an important therapeutic option for patients with relapsed and refractory B cell malignancies. However, recent clinical data indicate that a significant portion of patients still do not benefit from the therapy owing to various resistance mechanisms, including high expression of multiple inhibitory immune checkpoint receptors on activated CAR T cel...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: eb364677-1f10-52a2-829c-59bf976ea219
DOI: 10.1101/2020.11.07.372334

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Simultaneous, cell-intrinsic downregulation of PD-1 and TIGIT enhances the effector function of CD19-targeting CAR T cells and promotes an early-memory phenotypeDOI 10.1101/2020.11.07.372334Read

PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells.Semantic proximity Read

From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapySemantic proximity Read

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read

Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin LymphomaSemantic proximity Read

PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challengesSemantic proximity Read

Engineering better chimeric antigen receptor T cellsSemantic proximity Read

Chimeric antigen receptor-modified T cells strike backSemantic proximity Read

Development and clinical evaluation of non-viral genome specific targeted CAR T cells in relapsed/refractory B-cell non-Hodgkin lymphomaSemantic proximity Read

TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted anti-tumor T cells by facilitating costimulationSemantic proximity Read

Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.Semantic proximity Read

CAR-T design: Elements and their synergistic functionSemantic proximity Read

Sequential single cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin’s lymphomaSemantic proximity Read